Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-31 @ 2:18 AM
Study NCT ID:
NCT07313761
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2026-03-19
First Post:
2025-12-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-15
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-26
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-26
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-19
First Submit QC Date:
None
Study First Post Date:
2026-01-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-18
Last Update Post Date:
2026-03-19
Last Update Post Date Type:
ACTUAL